Angiogenesis, Coagulopathy and Endothelial Dysfunction in ANFH: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Monica Singh
,
Baani Singh
,
Kirti Sharma
,
Nitin Kumar
,
Sarabjit Mastana
,
Puneetpal Singh

Avascular necrosis of the femoral head (ANFH) is a painful disorder characterized by the cessation of blood supply to the femoral head, leading to its death and subsequent joint collapse. Influenced by several risk factors, including corticosteroid use, excessive alcohol intake, hypercholesterolemia, smoking and some inflammatory disorders, along with cancer, its clinical consequences are thrombus formation due to underlying inflammation and endothelial dysfunction, which collaborates with coagulopathy and impaired angiogenesis. Nonetheless, angiogenesis resolves the obstructed free flow of the blood by providing alternative routes. Clinical manifestations of early stage of ANFH mimic cysts or lesions in subchondral bone, vasculitis and transient osteoporosis of the hip, rendering it difficult to diagnose, complex to understand and complicated to cure. 

  • avascular necrosis of femoral head
  • impaired angiogenesis
  • coagulopathy
  • endothelial dysfunction
  • bone disease
  • skeletal abnormality

1. Introduction

Avascular necrosis of the femoral head (ANFH) is a debilitating condition identified as the death of the bone tissue due to compromised blood supply to the subchondral bone and its delayed regeneration [1]. Being a multifactorial and complex disease, its pathogenesis remains unclear. Several risk factors, including excessive alcohol intake; corticosteroid use; some medical conditions such as lupus, sickle cell disease and clotting disorders; and hormonal imbalances along with cancers and medical procedures like high-dose radiation therapy, hip surgery, bone marrow transplant and genetic factors participate in its pathology [2]. The effect of these risk factors generally induces dysfunction in the molecular pathways which initiate, develop and progress ANFH [3]. Three important pathways which may play a crucial role in ANFH pathology are impaired angiogenesis, coagulopathy and endothelial dysfunction [4]. Understanding the intricate and unforeseen interplay among these three molecular mechanisms is essential for unraveling the underlying pathways, which will help devise effective therapeutic strategies for ANFH [4]. Largely, ANFH is caused by hindered or cessation of blood supply to the femoral head, leading to necrosis because of an inadequate supply of oxygen and nutrients to the bone tissue (Figure 1). In response, a cascade of events is initiated for restoring impaired blood flow.
Figure 1. Impaired blood supply causing necrosis of the femoral head.

2. Angiogenesis: Sprouting, Splitting and Stabilization

Angiogenesis is a process of developing new vessels from pre-existing vessels, and these vessels are considered to be the foremost organ in embryo development [5]. Vessels may develop, remodel and grow in different ways. They may sprout from already present vessels (sprouting angiogenesis) or develop by splitting from previously prevailing arteries or capillaries upon receiving the angiogenic stimuli (intussusceptive) [6]. They may enlarge and elongate from the coalescence of capillaries (coalescent angiogenesis), promoting the rapid expansion of the vasculature. Vessels may remodel themselves to increase their luminal diameter when more blood flow is required or there is a need to develop collateral bridges to provide alternative routes for the free flow of blood (arteriogenesis) [7]. Unlike angiogenesis, new blood vessels may be formed from the blood islands where no pre-existing vessels are present (vasculogenesis) [6]. All newly formed vessels must be mature and stable, otherwise they may be abnormal and leaking, further causing problems of local hematoma and edema [8]. These become stable due to the signaling molecules arranging pericytes overlaid on endothelial cells and the formation of the basement membrane, whereby junctions are established to allow optimum blood flow [9]. Angiogenesis has both beneficial and detrimental effects on health and disease, which makes it a potent hotspot for both pro-angiogenic and anti-angiogenic drug targets [10].
From the perspective of avascular necrosis, regulated angiogenesis is beneficial for collateral circulation to the necrotic area and its repair, whereas dysregulated angiogenesis is harmful [11]. The femur is a specially structured and highly vascularized bone, the longest in the human body. Its mechanical strength, recuperation, repair, regeneration and remodeling depend upon vascular health, which helps in supplying incessant blood and providing adequate oxygen, nutrients, growth factors and osteoprogenitor cells to the bone [12]. Consequently, angiogenesis is expected to revascularize, reperfuse and resorb the necrotic area. Branching from the circulatory system, the nutrient artery is the largest blood vessel that enters the medullary cavity and supplies almost half of the total blood volume to the femur [13]. At the proximal end, it forms anastomoses with perforating arteries, whereas at the distal side it merges with the profunda femoris artery. It extends longitudinally to the bone and divides into the lateral femoral circumflex artery and medial femoral circumflex artery [14]. Both branches of lateral femoral circumflex arteries feed the femur head region via lateral epiphyseal arteries and the neck region through posterior superior retinacular arteries [15]. The ligament of the femur head is also supplied by the anterior branch of the obturator artery of the hip bone, which traverses through the inferior part of the pubic ramus and anastomoses with the femoral artery and medial femoral circumflex artery [16] (Figure 1).
With the advent of three-dimensional high-resolution imaging, a new aspect of the anatomy of vessels linking bone vasculature and bone marrow has been discovered [17]. This newly discovered vascular system comprises arterioles, venioles and capillaries, which collectively have been named as transcortical vessels (TCVs), which have shed light on the connection between endosteal and periosteal circulation [18]. A new subtype of blood vessels expressed from endomucin (Emcn) and a cluster of differentiation 31 (CD31) on endothelial cells in the bone known as type H has been identified lately [19]. Present in endosteum and metaphysis, this vessel is considered to be full of mesenchymal and osteoprogenitor cells, which mediate subchondral remodeling by coupling angiogenesis and osteogenesis [20]. Whether it contributes to ANFH pathology remains to be clarified as crosstalk between subchondral bone and articular cartilage during ischemia is unclear [21]. Obstruction or ischemia may take place in any of these arteries, but lateral and medial branches of the femoral circumflex or retinacular arteries are largely involved [22].

3. Angiogenesis: A Predominant Pacifier in Avascular Necrosis

Several stimuli are received by endothelial cells from the local environment, prompting them to initiate angiogenesis [23]. These signaling stimuli augment endothelial cell activation and their migration along with apoptotic resistance, cytoskeletal reorganization and endothelial cell proliferation. Firstly, angiogenesis is triggered in response to ischemia, which is a dynamic process leveraging the equilibrium between pro-angiogenic and anti-angiogenic factors, resulting in the expansion of the vascular network [24]. Several vasculature and bone-derived angiogenic factors and stimulators play a role in angiogenesis to counterbalance the exigencies of nutrients and oxygen to the necrotic area [25]. They are hypoxia inducible factor-1α (HIF1-α), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR), neuropilin 1 (NRP1), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), C-C motif chemokine ligand-2 (CCL-2), integrins αvβ3, αvβ5., vascular endothelial cadherin (VE-cadherin), cluster of differentiation 31 (CD31), plasminogen activators, inhibitor of DNA binding-1/inhibitor of DNA binding-3 (ID1/ID3), bone morphogenetic protein (BMP), prostaglandins (PTG), adenosine, pleiotrophin (PTN), delta-like canonical Notch ligand 4-Notch-Noggin (DLL4-NOTCH-NOG), receptor activator of nuclear factor-kappa β ligand/receptor activator of nuclear factor-kappa β/osteoprotegerin (RANKL/RANK/OPG), semaphorin (SEMA), nitric oxide (NO) and matrix metalloproteinases (MMPs) [26]. Nonetheless, molecular pathways between vasculature and bone interact and collaborate to initiate angiogenesis–osteogenesis coupling, which is required for the overall regeneration and repair of the necrotic area [27]. Endothelial cells along with pericytes initiate endocrine signaling, whereas osteoblasts and osteoclasts trigger angiogenesis to manage and maintain vasculature.
After ischemia, hypoxic conditions emerge, which induce HIF-1α and VEGF in response [28]. It has been considered that HIF-1α is the precursor for the upregulation of VEGF, which is corroborated by the finding that transplantation of HIF1-α with transgenic bone marrow cells onto the necrotic area upregulated VEGF and increased angiogenesis, resulting in the repair of the necrotic area [25]. The nuclear signal transduction augments the translocation of HIF1-α to form a complex with HIF1-β and transcriptional co-activator E1A-associated protein/CREB binding protein (p300/CBP), which helps them to bind with the hypoxia response element [29]. It translates into the activation of several angiogenic genes such as VEGF, ANGPT-2 and nitric oxide synthase (NOS). VEGF plays the main role in bone remodeling via differentiation of osteoblasts and promoting endothelial cells at the affected area [30]. Besides the involvement of other forms of VEGF (VEGF-B, VEGF-C, VEGF-D and placenta growth factor), VEGF-A is primarily involved in angiogenesis and vasculogenesis during ischemic insult by binding and activating both VEGF receptors, i.e., VEGFR-1 and VEGFR-2, for vascular permeability, cell migration, vascular function and vessel maintenance [31].
Besides promoting endothelial cell differentiation, migration and proliferation, VEGF initiates the recruitment of bone-marrow-derived endothelial progenitor cells at the affected area [32] (Figure 2). Consequently, it promotes morphogenesis of the growth plate, blood vessel formation and remodeling of the affected cartilage [33]. The mechanism of VEGF-induced angiogenesis is essential in cartilage revascularization at both early stage and end stage after necrosis [34]. It is expressed in the edematous area of the necrotic zone and plays a significant role in the repair of the ongoing hypoxia-induced osteonecrotic area [35]. In the absence of VEGF, angiogenesis has been observed to be arrested, and the process of trabecular and cortical bone repair is significantly attenuated [36]. Moreover, it directly influences the osteoblast activity by increasing nodule formation and alkaline phosphatase, thereby promoting mineralization in a dose-dependent manner [37]. This suggests that the upregulation of VEGF in osteoblasts during hypoxia participates in and contributes to the healing process by promoting initial calcification at the site of injury [38].
Figure 2. Angiogenic stimuli at cartilage and endothelium.
Endothelial cells have oxygen sensors and hypoxia-inducible factors: hypoxia-inducible factor-2 alpha (HIF-2α) and prolyl hydroxylase domain 2 (PHD2) [39]. After obtaining subtle hypoxemic stimuli, vessels start readjusting their size by vasodilation to receive blood flow. These endothelial cells adjust as a monolayer of phalanx cells and establish interconnections through the adhesion activity of VE-cadherin and claudins [40]. These layers are overlaid with pericytes, which signal for survival to VEGF and ANGPT-1. Angiogenic signaling is initiated due to hypoxia, and pericytes are separated from the vessel wall and detach from the basement membrane via proteolytic degradation controlled by MMPs [41]. Consequently, interconnections are loosened, and the naked vessel starts enlarging. Extracellular matrix support is provided by VEGF signaling, whereby endothelial cells migrate owing to integrin signaling [42]. Angiogenic molecules such as VEGF and FGF are released due to the action of proteases. Special endothelial cells, tip cells in the presence of factors such as VEGF receptors, DLL4-NOTCH, Jagged1 and neuropilins, form the tube-like structure and inhibit endothelial cells from migrating toward angiogenic signals [41]. Prompted and mediated by the signaling of NOTCH, WNTs, Placental growth factor (PlGF), FGF, NOTCH-regulated ankyrin repeat protein (NRARP), VE-cadherin, VEGF, Hedgehog and CD34, the tip cells of the flanking region are established as stalk cells, which split and extend to form lumen [43]. Local environmental stimuli are sensed by filopodia of the tip cells with the help of ephrins and semaphorins, whereas angiogenic signals are sensed by HIF-1α. In response, myeloid cells establish a link with another vessel, allowing the free flow of the blood [41]. These vessels must be stable and properly formed, otherwise they become leaky and promote hypoxia and ischemia [8]. To acquire maturity and stability, endothelial cells become quiescent, and these signals are responded to by NOTCH, PDGFB, ANGPT-1, TGF-β and ephrin-B2 to form a layer of pericytes on endothelial cells [44]. Some protease inhibitors such as tissue inhibitor metalloproteinases (TIMPs) and plasminogen activator inhibitor-1 (PAI-1) arrange the basement membrane, whereby junctions are formed to provide ideal blood flow. Vessels may regress if perfusion is not established [45].

4. Coagulopathy: A Culprit Alliance of Thrombophilia and Hypofibrinolysis

Following the revelation from the first study by Hamilton et al. in 1965, several studies have endorsed that the pathology of osteonecrosis resulting from vascular ischemia is strongly influenced by coagulopathy [46]. Intravascular coagulation and thrombosis coupled with excessive thrombophilia and hypofibrinolysis are the major reasons [47]. Thrombophilia, sometimes called hypercoagulability, is an abnormality of the clotting mechanism which promotes thrombus formation within walls of blood circulatory vessels. Thrombophilia predominantly develops into deep venous thrombosis (DVT) and pulmonary embolism (PE), two chief reasons for cardiovascular morbidity and mortality. Both of these hypercoagulable conditions are termed venous thromboembolism (VTE). VTE deteriorates fibrinolytic machinery causing hypofibrinolysis, an abnormal condition whereby clot-resolving factors are dysregulated and clot-forming conditions are promoted. Fibrinolysis is the process of breaking down thrombus or clots and is strictly regulated by activators such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) as well as inhibitors like tissue factor plasminogen inhibitor (TFPI) and plasminogen activator inhibitor-1 (PAI-1) and a fibrinolytic protease, plasmin. Plasminogen converts to plasmin via FXIa, FXIIa and kallikrein. This step triggers fibrinolysis by activating tPA within endothelial cells and uPA through the urinary epithelium, monocytes and macrophages. These factors play a significant role in breaking down and clearing clots from vasculature, whereas hypofibrinolysis (decreased levels of tPA and increased levels of PAI-1) impairs clot breakdown and prolongs its clearance. Several primary factors such as low levels of activated protein C (APC), protein S, factor V Leiden, activated protein C resistance (APCR), low levels of tPA or high levels of PAI-1, high levels of von Willebrand factor (vWF), high levels of lipoprotein(a) (Lp(a)) and homocystinuria along with secondary factors such as antiphospholipid antibodies, corticosteroid use, systemic lupus erythematosus (SLE) and caisson disease hemoglobinopathies, hemato-oncological diseases such as chronic myelogenous leukemia, acute lymphoblastic leukemia and multiple myeloma also participate in and contribute to causing hypofibrinolysis [47][48][49][50][51][52][53][54][55].
The coagulopathy cascade comprises a localized and speedy activation of inactive serine proteases (clotting factors) sequentially to generate thrombin resulting in clot formation (fibrin mesh) [56]. This pathway is triggered by sub-endothelial mural cells and fibroblasts of vascular adventitia. Coagulation may also trigger due to low levels of circulating polymorphonuclear neutrophils and monocytes/macrophages [57]. The first and foremost trigger is the exposure of tissue factor (TF) due to the severity of endothelial cell damage [58]. This exposed TF combines with factor VII to activate it to FVIIa, culminating in a sequence of activating factors such as FIX to FIXa and FX to FXa [59]. FXa turns prothrombin to thrombin, which further activates FV and FVIII to FVa and FVIIIa, a step responsible for converting prothrombin to thrombin by activating FX to FXa [59]. Furthermore, this thrombin-mediated fibrin clot is solidified by FXIa and interlinked by FXIIIa [60]. Activated platelets aggregate to form this clot as TF-presenting cells, ultimately augmenting coagulation and thrombus formation [61]. This process is simultaneously regulated by inhibitors of coagulation so that clot formation is not unnecessary and remains localized. TFPI, anti-thrombin (AT) and protein C are three major inhibitory molecules that check and resolve excessive coagulation within vessel walls [62] (Figure 3). Furthermore, the fibrinolytic pathway mediates vessel wall agility, integrity and healing.
Figure 3. Coagulation pathway in the pathology of avascular necrosis of the femoral head.
Innate immune response and inflammatory reaction play roles simultaneously within endothelium to resolve ensuing damage and support the healing process. Phagocytes, antigen-presenting cells, monocytes and neutrophils are prompted upon encountering danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) [63]. Consequently, activated monocytes and neutrophils initiate an immune response against cellular debris referred to as immunothrombosis, which emerges in response to atherosclerotic connotations within vessel walls. Vascular debris due to damaged endothelium and plaque formation is sensed by PAMPs and DAMPs and in response initiates tissue factor expression on monocytes and neutrophils, furthering immunothrombosis [64]. This unresolved and uncontrolled immunothrombosis forms disseminated intravascular coagulation (DIC). Side by side, DAMPs and PAMPs induce a proinflammatory cascade along with antimicrobial cytokines and chemokines by upregulation of intracellular cell adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) [63][64]. This mechanism plays a significant role in resolving the ischemic insult and repairing tissue damage. DAMPs were efficiently disposed of by initiating a complement activation cascade triggered by membrane-anchored proteins and soluble regulators.
Etiopathology of osteonecrosis of the femoral head is influenced by two molecular pathways, i.e., thrombophilia and hypofibrinolysis. Their clinical causative consequences are heightened intraosseous venous pressure and reduced arterial flow supporting hypoxia-induced ischemic insult in the bone vasculature. Both familial and acquired thrombophilia/hypofibrinolysis contribute to osteonecrosis of the jaw/hip in both children and adults [65]. Primarily, glucocorticoids attenuate fibrinolytic activity by increasing PAI-1 levels and decreasing tPA levels [66]. PAI-1 and tPA work in unison to resolve thrombosis by increasing fibrinolysis because their PAI-1/tPA complex inhibits plasmin generation from plasminogen. Glucocorticoids increase the functional activity of PAI-1 and reduce tPA levels, thereby triggering a hypercoagulable state [67][68]. Resulting in osteonecrosis of the femoral head, this thrombophilia-hypofibrinolysis duo is further supported by higher levels of fibrinogen and Lp(a) promoting platelet activation resulting in delayed lysis of thrombosis [69]. Furthermore, P1A1/A2 polymorphism in glycoprotein IIIa, lupus anticoagulant, reduced levels of protein C, S and anti-thrombin III along with cardiolipin antibodies contribute to the thrombophilia-hypofibrinolysis axis-induced osteonecrosis of the femoral head. In secondary ANFH, endothelial dysfunction rather than thrombophilia collaborates with hypofibrinolysis in worsening ANFH outcomes [70].

5. Endothelial Dysfunction: Holding Hands with Inflammation

The endothelium is a cell lining positioned on the inner surface of the blood vessels dividing circulating blood from the tissue. In response to various physical and chemical stimuli, such as perturbed blood flow, excessive intramural pressure, oxidative stress, cellular damage, high levels of homocysteine, hyperlipidemia, toxic chemicals and bacterial/viral infections, it initiates endocrine, paracrine and autocrine functions to produce vasodilators such as nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived hyperpolarizing factors (EDHFs) and vasoconstrictors such as endothelin-1 (ET-1) and thromboxane-A2 (TXA2) [71]. The endothelium regulates homeostasis by maintaining the balance between vasodilators and vasoconstrictors, anticoagulants and procoagulants, inflammatory and anti-inflammatory molecules, oxidants and antioxidants as well as profibrinolytics and antifibrinolytics (Figure 4) [72]. Due to several risk factors, this homeostasis is lost and is termed endothelial dysfunction. In prolonged endothelial dysfunction, cholesterol microcrystals, monocytes and lymphocytes enter layers of endothelium and initiate inflammatory response, which helps in the formation of fatty streaks resulting in plaque setup, its progression and rupture. Plaque rupture expounds thrombus formation, which couples with coagulation cascade, resulting in atherogenesis and vascular ischemia [73]. Alluding to its contribution to the pathology of several diseases, endothelial dysfunction has been recognized as the diagnostic and prognostic marker for developing atherosclerotic plaque at all phases of initiation, progression and its worst outcomes of plaque rupture [74].
Figure 4. Endothelial dysfunction showing impaired homeostasis and risk pathways.

6. Therapies Used in Other Diseases: A Possible Avenue for ANFH Management

ANFH attracted attention when it was confirmed that people with long COVID-19 are more vulnerable to ANFH [75][76]. The primary reason identified was the use of life-saving corticosteroids for patients suffering from COVID-19 [77]. Several therapies catering to resolve pain and improve structure function have been reported [78][79][80][81][82][83]. These therapies include core decompression (CD), small-diameter drilling CD, extracorporeal shockwave therapy (EPSW), microsurgical fibula flaps (MFFs) and combination therapies such as alendronate combined with EPSW or autologous bone marrow buffy coat grafting combined with CD. All these therapies are effective in reducing lesion volume, progression of necrosis and pain and improving the endothelial functional status of the femoral head to some extent but failed to resolve necrosis. This prompted us to also look at ANFH management from the perspective of other angles, which may help provide solutions as an adjunct therapy to abovementioned invasive therapies for the proper restoration of the blood supply for cleansing, repairing and healing the necrotic head. The present research has attempted to assimilate some current reports showing therapeutic solutions for promoting angiogenesis, blocking coagulopathy and improving endothelial function in other diseases including some bone diseases, which may open new vistas for better management of patients suffering from ANFH.
Some pro-angiogenic therapies such as reperfusion, VEGF, stem cells, PDGF, hyperbaric oxygen and gene therapy can be adapted and applied to different phases of ANFH pathology so that it can improve and restore blood supply and facilitate tissue repair and healing. Similarly, several thrombolytic and fibrinolytic therapies used to preserve coagulation homeostasis in acute limb ischemia, intracranial artery stenosis, non-ST-segment elevated myocardial infarction and acute coronary syndromes can be utilized in attempts to resolve emboli within vessel walls feeding blood to the necrotic area of the femoral head. Likewise, several therapies have been shown to improve endothelial function in cardiovascular diseases. It is reasonable to believe that without maintaining endothelial health, restoration of the free flow of blood to the bone remains incomplete. Therefore, therapies such as antioxidant therapy, using androgen receptor agonists such as ticagrelor, infusions of NO, statins, angiotensin-II receptor blockers, CircHIPK3 therapy and L-arginine therapy may demonstrate promising effects on the recovery of endothelial function, hence promoting repair, preserving bone remodeling and potentiating healing.

This entry is adapted from the peer-reviewed paper 10.3390/cells12182278

References

  1. Narayanan, A.; Khanchandani, P.; Borkar, R.M.; Ambati, C.R.; Roy, A.; Han, X.; Bhoskar, R.N.; Ragampeta, S.; Gannon, F.; Mysorekar, V.; et al. Avascular Necrosis of Femoral Head: A Metabolomic, Biophysical, Biochemical, Electron Microscopic and Histopathological Characterization. Sci. Rep. 2017, 7, 10721.
  2. George, G.; Lane, J.M. Osteonecrosis of the Femoral Head. J. Am. Acad. Orthop. Surg. Glob. Res. Rev. 2022, 6, e21.00176.
  3. Petek, D.; Hannouche, D.; Suva, D. Osteonecrosis of the Femoral Head: Pathophysiology and Current Concepts of Treatment. EFORT Open Rev. 2019, 4, 85–97.
  4. Kerachian, M.A.; Harvey, E.J.; Cournoyer, D.; Chow, T.Y.K.; Séguin, C. Avascular Necrosis of the Femoral Head: Vascular Hypotheses. Endothelium 2006, 13, 237–244.
  5. Kretschmer, M.; Rüdiger, D.; Zahler, S. Mechanical Aspects of Angiogenesis. Cancers 2021, 13, 4987.
  6. Semenza, G.L. Vasculogenesis, Angiogenesis, and Arteriogenesis: Mechanisms of Blood Vessel Formation and Remodeling. J. Cell. Biochem. 2007, 102, 840–847.
  7. Ashraf, J.V.; Al Haj Zen, A. Role of Vascular Smooth Muscle Cell Phenotype Switching in Arteriogenesis. Int. J. Mol. Sci. 2021, 22, 10585.
  8. Claesson-Welsh, L. Vascular Permeability--the Essentials. Upsala J. Med. Sci. 2015, 120, 135–143.
  9. Stratman, A.N.; Davis, G.E. Endothelial Cell-Pericyte Interactions Stimulate Basement Membrane Matrix Assembly: Influence on Vascular Tube Remodeling, Maturation, and Stabilization. Microsc. Microanal. 2012, 18, 68–80.
  10. Yoo, S.Y.; Kwon, S.M. Angiogenesis and Its Therapeutic Opportunities. Mediat. Inflamm. 2013, 2013, 127170.
  11. Smith, D.W. Is Avascular Necrosis of the Femoral Head the Result of Inhibition of Angiogenesis? Med. Hypotheses 1997, 49, 497–500.
  12. Wu, S.-H.; Miao, Y.; Zhu, X.-Z.; Li, G.-Y. . Zhongguo Gu Shang 2023, 36, 294–298.
  13. Kawasaki, Y.; Kinose, S.; Kato, K.; Sakai, T.; Ichimura, K. Anatomic Characterization of the Femoral Nutrient Artery: Application to Fracture and Surgery of the Femur. Clin. Anat. 2020, 33, 479–487.
  14. Rajani, S.J.; Ravat, M.K.; Rajani, J.K.; Bhedi, A.N. Cadaveric Study of Profunda Femoris Artery with Some Unique Variations. J. Clin. Diagn. Res. 2015, 9, AC01–AC03.
  15. Zhao, D.; Qiu, X.; Wang, B.; Wang, Z.; Wang, W.; Ouyang, J.; Silva, R.M.; Shi, X.; Kang, K.; Xu, D.; et al. Epiphyseal Arterial Network and Inferior Retinacular Artery Seem Critical to Femoral Head Perfusion in Adults With Femoral Neck Fractures. Clin. Orthop. Relat. Res. 2017, 475, 2011–2023.
  16. Lee, E.-J.; Jain, M.; Alimperti, S. Bone Microvasculature: Stimulus for Tissue Function and Regeneration. Tissue Eng. Part B Rev. 2021, 27, 313–329.
  17. Grüneboom, A.; Kling, L.; Christiansen, S.; Mill, L.; Maier, A.; Engelke, K.; Quick, H.H.; Schett, G.; Gunzer, M. Next-Generation Imaging of the Skeletal System and Its Blood Supply. Nat. Rev. Rheumatol. 2019, 15, 533–549.
  18. Grüneboom, A.; Hawwari, I.; Weidner, D.; Culemann, S.; Müller, S.; Henneberg, S.; Brenzel, A.; Merz, S.; Bornemann, L.; Zec, K.; et al. A Network of Trans-Cortical Capillaries as Mainstay for Blood Circulation in Long Bones. Nat. Metab. 2019, 1, 236–250.
  19. Kusumbe, A.P.; Ramasamy, S.K.; Adams, R.H. Coupling of Angiogenesis and Osteogenesis by a Specific Vessel Subtype in Bone. Nature 2014, 507, 323–328.
  20. Xu, Z.; Kusumbe, A.P.; Cai, H.; Wan, Q.; Chen, J. Type H Blood Vessels in Coupling Angiogenesis-Osteogenesis and Its Application in Bone Tissue Engineering. J. Biomed. Mater. Res. B Appl. Biomater. 2023, 111, 1434–1446.
  21. Liu, Y.; Xie, H.-Q.; Shen, B. Type H Vessels-a Bridge Connecting Subchondral Bone Remodelling and Articular Cartilage Degeneration in Osteoarthritis Development. Rheumatology 2023, 62, 1436–1444.
  22. Zheng, G.-S.; Qiu, X.; Wang, B.-J.; Zhao, D.-W. Relationship Between Blood Flow and Collapse of Nontraumatic Osteonecrosis of the Femoral Head. J. Bone Jt. Surg. Am. 2022, 104, 13–18.
  23. Muñoz-Chápuli, R.; Quesada, A.R.; Angel Medina, M. Angiogenesis and Signal Transduction in Endothelial Cells. Cell. Mol. Life Sci. 2004, 61, 2224–2243.
  24. Kazerounian, S.; Lawler, J. Integration of Pro- and Anti-Angiogenic Signals by Endothelial Cells. J. Cell Commun. Signal. 2018, 12, 171–179.
  25. Ding, H.; Gao, Y.-S.; Hu, C.; Wang, Y.; Wang, C.-G.; Yin, J.-M.; Sun, Y.; Zhang, C.-Q. HIF-1α Transgenic Bone Marrow Cells Can Promote Tissue Repair in Cases of Corticosteroid-Induced Osteonecrosis of the Femoral Head in Rabbits. PLoS ONE 2013, 8, e63628.
  26. Felmeden, D.C.; Blann, A.D.; Lip, G.Y.H. Angiogenesis: Basic Pathophysiology and Implications for Disease. Eur. Heart J. 2003, 24, 586–603.
  27. Han, Y.; You, X.; Xing, W.; Zhang, Z.; Zou, W. Paracrine and Endocrine Actions of Bone-the Functions of Secretory Proteins from Osteoblasts, Osteocytes, and Osteoclasts. Bone Res. 2018, 6, 16.
  28. Dor, Y.; Keshet, E. Ischemia-Driven Angiogenesis. Trends Cardiovasc. Med. 1997, 7, 289–294.
  29. Corrado, C.; Fontana, S. Hypoxia and HIF Signaling: One Axis with Divergent Effects. Int. J. Mol. Sci. 2020, 21, 5611.
  30. Hu, K.; Olsen, B.R. The Roles of Vascular Endothelial Growth Factor in Bone Repair and Regeneration. Bone 2016, 91, 30–38.
  31. Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2011, 2, 1097–1105.
  32. Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J.M. VEGF Contributes to Postnatal Neovascularization by Mobilizing Bone Marrow-Derived Endothelial Progenitor Cells. EMBO J. 1999, 18, 3964–3972.
  33. Yang, Y.-Q.; Tan, Y.-Y.; Wong, R.; Wenden, A.; Zhang, L.-K.; Rabie, A.B.M. The Role of Vascular Endothelial Growth Factor in Ossification. Int. J. Oral Sci. 2012, 4, 64–68.
  34. Zelzer, E.; Mamluk, R.; Ferrara, N.; Johnson, R.S.; Schipani, E.; Olsen, B.R. VEGFA Is Necessary for Chondrocyte Survival during Bone Development. Development 2004, 131, 2161–2171.
  35. Radke, S.; Battmann, A.; Jatzke, S.; Eulert, J.; Jakob, F.; Schütze, N. Expression of the Angiomatrix and Angiogenic Proteins CYR61, CTGF, and VEGF in Osteonecrosis of the Femoral Head. J. Orthop. Res. 2006, 24, 945–952.
  36. Zhang, C.; Li, Y.; Cornelia, R.; Swisher, S.; Kim, H. Regulation of VEGF Expression by HIF-1α in the Femoral Head Cartilage Following Ischemia Osteonecrosis. Sci. Rep. 2012, 2, 650.
  37. Street, J.; Bao, M.; deGuzman, L.; Bunting, S.; Peale, F.V.; Ferrara, N.; Steinmetz, H.; Hoeffel, J.; Cleland, J.L.; Daugherty, A.; et al. Vascular Endothelial Growth Factor Stimulates Bone Repair by Promoting Angiogenesis and Bone Turnover. Proc. Natl. Acad. Sci. USA 2002, 99, 9656–9661.
  38. Hu, K.; Olsen, B.R. Osteoblast-Derived VEGF Regulates Osteoblast Differentiation and Bone Formation during Bone Repair. J. Clin. Investig. 2016, 126, 509–526.
  39. Kapitsinou, P.P.; Rajendran, G.; Astleford, L.; Michael, M.; Schonfeld, M.P.; Fields, T.; Shay, S.; French, J.L.; West, J.; Haase, V.H. The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice. Mol. Cell. Biol. 2016, 36, 1584–1594.
  40. Gavard, J.; Gutkind, J.S. VE-Cadherin and Claudin-5: It Takes Two to Tango. Nat. Cell Biol. 2008, 10, 883–885.
  41. Carmeliet, P.; Jain, R.K. Molecular Mechanisms and Clinical Applications of Angiogenesis. Nature 2011, 473, 298–307.
  42. Hutchings, H.; Ortega, N.; Plouët, J. Extracellular Matrix-Bound Vascular Endothelial Growth Factor Promotes Endothelial Cell Adhesion, Migration, and Survival through Integrin Ligation. FASEB J. 2003, 17, 1520–1522.
  43. Phng, L.-K.; Potente, M.; Leslie, J.D.; Babbage, J.; Nyqvist, D.; Lobov, I.; Ondr, J.K.; Rao, S.; Lang, R.A.; Thurston, G.; et al. Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis. Dev. Cell 2009, 16, 70–82.
  44. Bergers, G.; Song, S. The Role of Pericytes in Blood-Vessel Formation and Maintenance. Neuro-Oncology 2005, 7, 452–464.
  45. Noel, A.; Maillard, C.; Rocks, N.; Jost, M.; Chabottaux, V.; Sounni, N.E.; Maquoi, E.; Cataldo, D.; Foidart, J.M. Membrane Associated Proteases and Their Inhibitors in Tumour Angiogenesis. J. Clin. Pathol. 2004, 57, 577–584.
  46. Vosmaer, A.; Pereira, R.R.; Koenderman, J.S.; Rosendaal, F.R.; Cannegieter, S.C. Coagulation Abnormalities in Legg-Calvé-Perthes Disease. J. Bone Jt. Surg. Am. 2010, 92, 121–128.
  47. Dahlbäck, B.; Carlsson, M.; Svensson, P.J. Familial Thrombophilia Due to a Previously Unrecognized Mechanism Characterized by Poor Anticoagulant Response to Activated Protein C: Prediction of a Cofactor to Activated Protein C. Proc. Natl. Acad. Sci. USA 1993, 90, 1004–1008.
  48. Svensson, P.J.; Dahlbäck, B. Resistance to Activated Protein C as a Basis for Venous Thrombosis. N. Engl. J. Med. 1994, 330, 517–522.
  49. Molino, D.; De Santo, N.G.; Marotta, R.; Anastasio, P.; Mosavat, M.; De Lucia, D. Plasma Levels of Plasminogen Activator Inhibitor Type 1, Factor VIII, Prothrombin Activation Fragment 1+2, Anticardiolipin, and Antiprothrombin Antibodies Are Risk Factors for Thrombosis in Hemodialysis Patients. Semin. Nephrol. 2004, 24, 495–501.
  50. Zwaginga, J.J.; Ijsseldijk, M.J.; Beeser-Visser, N.; de Groot, P.G.; Vos, J.; Sixma, J.J. High von Willebrand Factor Concentration Compensates a Relative Adhesion Defect in Uremic Blood. Blood 1990, 75, 1498–1508.
  51. Fortmann, S.P.; Marcovina, S.M. Lipoprotein(a), a Clinically Elusive Lipoprotein Particle. Circulation 1997, 95, 295–296.
  52. Hughes, G.R. The Antiphospholipid Syndrome: Ten Years On. Lancet 1993, 342, 341–344.
  53. Mont, M.A.; Jones, L.C.; Hungerford, D.S. Nontraumatic Osteonecrosis of the Femoral Head: Ten Years Later. J. Bone Jt. Surg. Am. 2006, 88, 1117–1132.
  54. Dubois, E.L.; Cozen, L. Avascular (Aseptic) Bone Necrosis Associated with Systemic Lupus Erythematosus. JAMA 1960, 174, 966–971.
  55. Ware, H.E.; Brooks, A.P.; Toye, R.; Berney, S.I. Sickle Cell Disease and Silent Avascular Necrosis of the Hip. J. Bone Jt. Surg. Br. 1991, 73, 947–949.
  56. Sondag, D.; Verhoeven, S.; Löwik, D.W.P.M.; van Geffen, M.; Veer, C.V.; van Heerde, W.L.; Boltje, T.J.; Rutjes, F.P.J.T. Activity Sensing of Coagulation and Fibrinolytic Proteases. Chemistry 2023, 29, e202203473.
  57. Noubouossie, D.F.; Reeves, B.N.; Strahl, B.D.; Key, N.S. Neutrophils: Back in the Thrombosis Spotlight. Blood 2019, 133, 2186–2197.
  58. Butenas, S.; Orfeo, T.; Mann, K.G. Tissue Factor in Coagulation: Which? Where? When? Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1989–1996.
  59. Palta, S.; Saroa, R.; Palta, A. Overview of the Coagulation System. Indian J. Anaesth. 2014, 58, 515–523.
  60. Schmitz, T.; Bäuml, C.A.; Imhof, D. Inhibitors of Blood Coagulation Factor XIII. Anal. Biochem. 2020, 605, 113708.
  61. Periayah, M.H.; Halim, A.S.; Mat Saad, A.Z. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. Int. J. Hematol. Oncol. Stem Cell Res. 2017, 11, 319–327.
  62. Sachs, U.J.; Kirsch-Altena, A.; Müller, J. Markers of Hereditary Thrombophilia with Unclear Significance. Hamostaseologie 2022, 42, 370–380.
  63. Meager, A. Cytokine Regulation of Cellular Adhesion Molecule Expression in Inflammation. Cytokine Growth Factor Rev. 1999, 10, 27–39.
  64. Ito, T. PAMPs and DAMPs as Triggers for DIC. J. Intensive Care 2014, 2, 67.
  65. Glueck, C.J.; Freiberg, R.A.; Wang, P. Role of Thrombosis in Osteonecrosis. Curr. Hematol. Rep. 2003, 2, 417–422.
  66. van Giezen, J.J.; Jansen, J.W. Correlation of in Vitro and in Vivo Decreased Fibrinolytic Activity Caused by Dexamethasone. Ann. N. Y. Acad. Sci. 1992, 667, 199–201.
  67. Kerachian, M.A.; Séguin, C.; Harvey, E.J. Glucocorticoids in Osteonecrosis of the Femoral Head: A New Understanding of the Mechanisms of Action. J. Steroid Biochem. Mol. Biol. 2009, 114, 121–128.
  68. Glueck, C.J.; Fontaine, R.N.; Gruppo, R.; Stroop, D.; Sieve-Smith, L.; Tracy, T.; Wang, P. The Plasminogen Activator Inhibitor-1 Gene, Hypofibrinolysis, and Osteonecrosis. Clin. Orthop. Relat. Res. 1999, 366, 133–146.
  69. Pósán, E.; Hársfalvi, J.; Szepesi, K.; Gáspár, L.; Batár, P.; Udvardy, M. Increased Platelet Activation and Decreased Fibrinolysis in the Pathogenesis of Aseptic Necrosis of the Femoral Head. Platelets 1998, 9, 233–235.
  70. Zhang, Q.; Lv, J.; Jin, L. Role of Coagulopathy in Glucocorticoid-Induced Osteonecrosis of the Femoral Head. J. Int. Med. Res. 2018, 46, 2141–2148.
  71. Pacinella, G.; Ciaccio, A.M.; Tuttolomondo, A. Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases. Int. J. Mol. Sci. 2022, 23, 15722.
  72. Esper, R.J.; Nordaby, R.A.; Vilariño, J.O.; Paragano, A.; Cacharrón, J.L.; Machado, R.A. Endothelial Dysfunction: A Comprehensive Appraisal. Cardiovasc. Diabetol. 2006, 5, 4.
  73. Wolf, D.; Ley, K. Immunity and Inflammation in Atherosclerosis. Circ. Res. 2019, 124, 315–327.
  74. Fan, T.; Song, Y.-J.; Liu, X.-L. Adenocarcinoma of the Lung with Concomitant ALK Fusion Gene and EGFR Gene Mutation: A Case Report and Literature Review. Mol. Clin. Oncol. 2016, 4, 203–205.
  75. Parikh, S.; Gomez, O.; Davis, T.; Lyon, Z.; Corces, A. Avascular Necrosis as a Sequela of COVID-19: A Case Series. Cureus 2023, 15, e35368.
  76. Agarwala, S.R.; Vijayvargiya, M.; Sawant, T. Secondary Osteonecrosis of the Knee as a Part of Long COVID-19 Syndrome: A Case Series. BMJ Case Rep. 2022, 15, e248583.
  77. Hassan, A.A.A.; Khalifa, A.A. Femoral Head Avascular Necrosis in COVID-19 Survivors: A Systematic Review. Rheumatol. Int. 2023, 43, 1583–1595.
  78. Hong, Y.-C.; Zhong, H.-M.; Lin, T.; Shi, J.-B. Comparison of Core Decompression and Conservative Treatment for Avascular Necrosis of Femoral Head at Early Stage: A Meta-Analysis. Int. J. Clin. Exp. Med. 2015, 8, 5207–5216.
  79. Tan, Y.; He, H.; Wan, Z.; Qin, J.; Wen, Y.; Pan, Z.; Wang, H.; Chen, L. Study on the Outcome of Patients with Aseptic Femoral Head Necrosis Treated with Percutaneous Multiple Small-Diameter Drilling Core Decompression: A Retrospective Cohort Study Based on Magnetic Resonance Imaging and Equivalent Sphere Model Analysis. J. Orthop. Surg. Res. 2020, 15, 264.
  80. Hong, Y.-C.; Luo, R.-B.; Lin, T.; Zhong, H.-M.; Shi, J.-B. Efficacy of Alendronate for Preventing Collapse of Femoral Head in Adult Patients with Nontraumatic Osteonecrosis. BioMed Res. Int. 2014, 2014, 716538.
  81. Ma, Y.; Wang, T.; Liao, J.; Gu, H.; Lin, X.; Jiang, Q.; Bulsara, M.K.; Zheng, M.; Zheng, Q. Efficacy of Autologous Bone Marrow Buffy Coat Grafting Combined with Core Decompression in Patients with Avascular Necrosis of Femoral Head: A Prospective, Double-Blinded, Randomized, Controlled Study. Stem Cell Res. Ther. 2014, 5, 115.
  82. Tang, H.-Y.; Zhao, Y.; Li, Y.-Z.; Wang, T.-S. Effectiveness of Extracorporeal Shock Wave Monotherapy for Avascular Necrosis of Femoral Head: A Systematic Review Protocol of Randomized Controlled Trial. Medicine 2019, 98, e15119.
  83. Tu, Y.; Chen, Z.; Lineaweaver, W.C.; Zhang, F. Different Recipient Vessels for Free Microsurgical Fibula Flaps in the Treatment of Avascular Necrosis of the Femoral Head: A Systematic Review and Meta-Analysis. Ann. Plast. Surg. 2017, 79, 583–589.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback